section name header

Indications ⬇

High Alert

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CV: chest pain

Derm: alopecia, rash

F and E: hyponatremia

GI: constipation, nausea, ↑liver enzymes, abdominal pain, anorexia, diarrhea, vomiting

Hemat: anemia, neutropenia, THROMBOCYTOPENIA

Local: irritation (at IV site), phlebitis

MS: arthralgia, back pain, jaw pain, myalgia

Neuro: fatigue, neurotoxicity

Resp: shortness of breath

Interactions ⬆ ⬇

Drug-drug:

Availability ⬆ ⬇

(Generic available)

Route/Dosage ⬆ ⬇

Hepatic Impairment

US Brand Names ⬆ ⬇

Navelbine

Action ⬆ ⬇

  • Binds to a protein (tubulin) of cellular microtubules, where it interferes with microtubule assembly. Cell replication is stopped as a result (cell cycle-specific for M phase).
Therapeutic effects:
  • Death of rapidly replicating cells, particularly malignant ones.

Classifications ⬆ ⬇

Therapeutic Classification: antineoplastics

Pharmacologic Classification: vinca alkaloids

Pharmacokinetics ⬆ ⬇

Absorption: IV administration results in complete bioavailability.

Distribution: Highly bound to platelets and lymphocytes.

Metabolism/Excretion: Mostly metabolized by the liver. ≥1 metabolite is active. Large amounts eliminated in feces; 11% excreted unchanged by the kidneys.

Half-Life: 28–44 hr.

Time/Action Profile ⬆ ⬇

(effect on WBCs)

ROUTEONSETPEAKDURATION
IVunknown7–10 days7–15 days

Patient/Family Teaching ⬆ ⬇

  • Explain purpose and side effects of medication. Advise patient to read Patient Information before starting therapy.
  • Instruct patient to notify health care provider immediately if redness, swelling, or pain at injection site occurs.
  • Instruct patient to report symptoms of neurotoxicity (numbness and tingling, pain, difficulty walking, persistent or severe constipation, abdominal pain). Advise patient to ↑ fluid intake, dietary fiber, and exercise to minimize constipation; stool softeners or laxatives may be used.
  • Advise patient to notify health care provider of signs and symptoms of urinary retention (difficulty urinating, weak stream, abdominal pain).
  • Advise patient to notify health care provider of fever; chills; sore throat; signs of infection; bleeding gums; bruising; petechiae; blood in urine, stool, or emesis; or mouth sores. Caution patient to avoid crowds and persons with known infections.
  • Discuss with patient the possibility of hair loss and explore coping strategies.
  • Emphasize the need for periodic lab tests to monitor for side effects.
  • Instruct patient not to receive any vaccinations without advice of health care provider.
  • Rep: May cause fetal harm. Advise women of reproductive potential to use effective contraception during therapy and ≥2 mo after last dose and to avoid breastfeeding during and for 9 days after last dose.

Pronunciation ⬆ ⬇

vine-oh-REL-been

Code ⬆

NDC Code